The canine vaccines market focuses on vaccines developed to protect dogs from infectious diseases such as rabies, distemper, parvovirus, adenovirus, leptospirosis, and parainfluenza. These vaccines are vital for maintaining pet health, preventing disease outbreaks, and reducing the spread of zoonotic infections that can affect humans. Market growth is driven by increasing pet ownership worldwide, rising awareness of animal health, and expanding veterinary healthcare infrastructure. Regular vaccination programs and government-led initiatives to control rabies and other infectious diseases also contribute to market expansion. Additionally, advancements in recombinant and combination vaccines are improving efficacy and convenience for both pet owners and veterinarians.
The global canine vaccines market size was valued at USD 1.87 billion in 2024 and is projected to grow from USD 1.95 billion in 2025 to USD 3.04 billion by 2032, exhibiting a CAGR of 6.5% during the forecast period. North America dominated the canine vaccines market with a market share of 44.91% in 2024, driven by increasing pet ownership, growing awareness about preventive healthcare for dogs, and robust veterinary infrastructure.